Results 151 to 160 of about 3,163 (211)
An Overview of Endometriosis and Potential Pharmacogenetic Targets. [PDF]
Pérez-Gómez N +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pharmacokinetics of Desogestrel
American Journal of Obstetrics and Gynecology, 1993A synthetic form of desogestrel, a gonane progestin, was developed because desogestrel's enhanced selectivity eliminates adverse, androgen-dependent, metabolic effects at contraceptive doses. Desogestrel is rapidly and completely metabolized in the liver and gut wall to 3-keto-desogestrel, which is the active metabolite mediating the progestin effects.
H D, McClamrock, E Y, Adashi
exaly +3 more sources
Pharmacokinetic Evaluation of Desogestrel as a Female Contraceptive
Desogestrel (DSG) is a third-generation 19-nortestosterone derivative progestogen. It is contained in many oral contraceptive preparations, both combined (COCs) to ethinyl-estradiol (EE) or alone in a progestin-only pill (POP).
Giovanni Grandi +2 more
exaly +2 more sources
Drug Safety Evaluation of Desogestrel
Introduction: Desogestrel (DSG) is a third-generation progestin. It is commonly used in various formulations for hormonal contraception including combinations with ethinyl estradiol (EE), progestin-only pill and subdermal implants.
Carolina Scala +2 more
exaly +2 more sources
Clinical Obstetrics and Gynecology, 1995
Desogestrel is a new, potent progestogen with very low androgenic properties. When used as a contraceptive, it is a strong antiovulatory compound, even at low doses. The clinical efficacy is as good as that of the old progestogens. It has a low incidence of side effects and complications, similar to other progestogens.
openaire +2 more sources
Desogestrel is a new, potent progestogen with very low androgenic properties. When used as a contraceptive, it is a strong antiovulatory compound, even at low doses. The clinical efficacy is as good as that of the old progestogens. It has a low incidence of side effects and complications, similar to other progestogens.
openaire +2 more sources
Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel
Contraception, 1986In a cross-over study with orally administered desogestrel (0.150 mg) plus ethinyloestradiol (0.030 mg) and 3-keto-desogestrel (0.150 mg) plus ethinyloestradiol (0.030 mg) in ten women under steady-state conditions, the serum levels of 3-keto-desogestrel were monitored by radioimmunoassay.
H G, Hasenack, A M, Bosch, K, Käär
openaire +2 more sources
Selectivity information on desogestrel
American Journal of Obstetrics and Gynecology, 1993Improvement in oral contraceptive formulations was originally achieved through dose reduction of the estrogen and progestogen components. Recently, further improvement was achieved by increasing the selectivity of contraceptive progestins. The ratio between the affinity for the progesterone receptor and the affinity for the androgen receptor is an ...
openaire +2 more sources
Contraception, 1987
The plasma concentrations of 3-keto-desogestrel have been measured by radioimmunoassay in a crossover study in nine healthy female volunteers given oral desogestrel (150 micrograms) and ethinyloestradiol (30 micrograms) and intravenous (i.v.) 3-keto-desogestrel (150 micrograms) and ethinyloestradiol (30 micrograms).
D J, Back +3 more
openaire +2 more sources
The plasma concentrations of 3-keto-desogestrel have been measured by radioimmunoassay in a crossover study in nine healthy female volunteers given oral desogestrel (150 micrograms) and ethinyloestradiol (30 micrograms) and intravenous (i.v.) 3-keto-desogestrel (150 micrograms) and ethinyloestradiol (30 micrograms).
D J, Back +3 more
openaire +2 more sources

